Praxis Precision Medicines (PRAX) Free Cash Flow (2019 - 2026)

Praxis Precision Medicines' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$86.2 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 62.32% year-over-year to -$86.2 million in Q1 2026; TTM through Mar 2026 was -$282.2 million, a 72.1% decrease from a year earlier, with the FY2025 full-year figure at -$249.1 million, down 89.08% from the prior year.
• Free Cash Flow fell to -$86.2 million in Q1 2026 per PRAX's latest filing, from -$76.3 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$20.9 million in Q1 2024 and bottomed at -$86.2 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$44.5 million (2022), against an average of -$44.9 million.
• Across the five-year window, Free Cash Flow jumped 47.74% in 2023 and tumbled 154.47% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$29.2 million in 2022, then advanced by 18.42% to -$23.9 million in 2023, then sank by 135.2% to -$56.1 million in 2024, then tumbled by 36.0% to -$76.3 million in 2025, then retreated by 12.88% to -$86.2 million in 2026.
• Per Business Quant, the three latest PRAX Free Cash Flow figures stand at -$86.2 million (Q1 2026), -$76.3 million (Q4 2025), and -$65.0 million (Q3 2025).